Inhibiting SLC38A2 lowers blood pressure in rodent models of hypertension

rs1873793 variant was associated with increased risk of hypertension under a recessive model. Collectively, our findings demonstrate that targeting SLC38A2 may represent a therapeutic target for the treatment of hypertension.